- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01453881
Fine Particle pMDI Formoterol/Beclomethasone in Asthmatics With and Without Spacer: Comparative Efficacy Evaluation (EFFECT-EV)
Randomized Clinical Trials to Compare Asthma Control Efficacy of the Fine-particle Combination Formoterol/Beclomethasone by pMDI Administered With and Without Spacer.
Study Overview
Detailed Description
This is a randomized, parallel controlled study with blind outcome evaluation to compare the efficacy of the fine particle combination Beclomethasone/Formoterol administered with or without valved holding chamber (Vortex, Pari Innovative Manufacturers, VA - USA.
Eligible asthma patients will begin a 2-weeks run-in period to optimize their control medication use and to learn the correct relief pMDI use without holding chamber. After the run-in, patients with non-controled asthma symptoms (ACT score 19 or under)in spite the use of medium to high dose inhaled steroids and LABA association and able to use correctly the pMDI will be randomized (block-randomization) to receive the test medication combination to be used with or without the spacer device (VORTEX). Patients will be evaluated after 30 and 60 days. At days 15 (+,- 2) and 45 (+,- 2) they will have an incentive phone call.
ACT score (translated and validated to portuguese - Brazil), FEV1 (Kit-Micro spirometer, Cosmed, Italy), pMDI use and clinical evaluation will be obtained at initial visit (visit 0), randomization visit (visit 1)and at 30 and 60 days (visits 2 and 3). Extra-medication allowed at run-in period will be inhaled beta-2 bronchodilators for relief an at treatment period inhaled beta-2 agonists for relief and systemic steroids for exacerbations, with antibiotics as needed.
Endpoint evaluations will be proceeded by a treatment blinded investigator.In order to keep the concealment, the evaluations will be held in a different room and the patients instructed not to comment on treatment.
Subjects will be excluded at the treatment period in case of severe asthma exacerbation (hospital or ICU recovery or systemic steroid used for more than 5 days). They will be excluded also in case of concomitant ailments at discretion of the attending physician. These patients will be excluded from the per-protocol evaluation but will be described.
Sample size was calculated taking into account a relevant ACT score difference of 3 points and a SD of 4.4 (SCHATZ M et all. Asthma Control Test: reliability, validity, and responsiveness in patients not previously followed by asthma specialists. J Allergy Clin Immunol 2006;117:549-56). In order to be able to detect this difference with α and β errors of 5% and 20% respectively, the investigators calculated 32 patients per group.
Statistical analysis will be carried according to data distribution by a professional statistician.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Pernambuco
-
Recife, Pernambuco, Brazil, 50740-520
- Hospital das Clinicas - Universidade Federal de Pernambuco
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adult, age 18 to 65 years, both sexes;
- Clinical diagnosis of moderate to severe persistent asthma;
- Nonsmoker;
- Agree to participate and sign the Informed Consent;
- ACT Score <= 19
- FEV1 <= 80% of predicted;
- History of response to FEV1 greater than 10%;
- Patients who are already using Inhaled steroids at medium to high doses (Beclomethasone, budesonide, fluticasone) with longa-acting beta2 agonists (formoterol or salmeterol)
- Proper use of metered-dose inhaler (after orientation)
Exclusion Criteria:
- Patient diagnosed with Chronic Obstructive Pulmonary Disease (COPD);
- Current smokers or have stopped for less than 10 years;
- Patients with a history of recent near-fatal asthma (less than 12 months);
- Patients with a history of recent asthma hospitalization (last 6 months);
- Patients with airway infection symptoms for less than 4 weeks;
- Participation in any experimental study up to 1 (one) year from selection visit;
- Hospitalization for any reason up to 8 weeks before selection visit;
- History of liver, cardiac, renal, pulmonary or gastrointestinal diseases, epileptic, psychiatric or hematologic disorders, uncontrolled hypertension, rheumatology/orthopedic disorders that interferes with pMDI use;
- Patients unable to properly use the pMDI during the selection
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Spacer
Beclomethasone/Formoterol 100/6mcg/puff pMDI 2 puffs two times/day with the aid of a Valved Holding Chamber - VORTEX
|
Beclomethasone/Formoterol 100/6mcg pMDI 2 puffs two times/day with the aid of a Valved Holding Chamber - VORTEX
Other Names:
|
ACTIVE_COMPARATOR: Comparator
Beclomethasone/Formoterol pMDI 100/6mcg/puff pMDI 2 puffs two times/day without the aid of a Valved Holding Chamber - VORTEX
|
Beclomethasone/Formoterol 100/6mcg pMDI 2 puffs two times/day without the aid of a Valved Holding Chamber - VORTEX
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Asthma Control Test Score
Time Frame: 8 weeks
|
The primary endpoint is the difference in the change of ACT score between groups 8 weeks after randomization compared to pre-randomization.
|
8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in Forced Expiratory Volume in the first second (FEV1)
Time Frame: 4 and 8 weeks
|
The secondary endpoint is the difference in the change on FEV1 between groups at 4 and 8 weeks after randomization compared to pre-randomization.
|
4 and 8 weeks
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Jose A Rizzo, PhD, MD, Universidade Federal de Pernambuco
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Immune System Diseases
- Lung Diseases
- Hypersensitivity, Immediate
- Bronchial Diseases
- Lung Diseases, Obstructive
- Respiratory Hypersensitivity
- Hypersensitivity
- Asthma
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Adrenergic Agonists
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Adrenergic beta-2 Receptor Agonists
- Adrenergic beta-Agonists
- Beclomethasone
- Formoterol Fumarate
Other Study ID Numbers
- PTC 034/11
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Asthma
-
Vanderbilt University Medical CenterNot yet recruitingAsthma in Children | Asthma Attack | Asthma Acute | Acute Asthma Exacerbation | Asthma; StatusUnited States
-
University of California, San FranciscoCompletedAsthma in Children | Asthma Attack | Asthma Acute | Asthma ChronicUnited States
-
SingHealth PolyclinicsNot yet recruitingAsthma | Asthma in Children | Asthma Attack | Asthma Acute | Asthma Chronic
-
Johann Wolfgang Goethe University HospitalCompleted
-
Universita di VeronaCompleted
-
Parc de Salut MarActive, not recruitingAsthma in Children | Persistent Asthma | Asthma ExacerbationSpain
-
Forest LaboratoriesCompleted
-
Brunel UniversityKarolinska InstitutetUnknown
-
Value Outcomes Ltd.AstraZenecaCompletedAsthma, Bronchial | Bronchial Asthma | Asthma Chronic | Asthma; EosinophilicCzechia
Clinical Trials on Spacer
-
University of OuluOulu University HospitalTerminatedUrogenital Neoplasms | Neoplasms by Site | Genital Neoplasms, Male | Prostatic NeoplasmsFinland
-
Spineology, IncCompletedDegeneration of Lumbar Intervertebral DiscUnited States
-
Globus Medical IncTerminatedLumbar Spinal StenosisUnited States
-
University of CologneTerminatedLumbar Spinal StenosisGermany
-
Artimplant ABUnknown
-
Northwestern UniversityNot yet recruitingArthroplasty, Replacement, Knee | Arthroplasty Complications | Joint Infection | Prosthetic-joint Infection | Knee InfectionUnited States
-
Chang Gung Memorial HospitalUnited Orthopedic CorporationRecruitingKnee; Infection, JointTaiwan
-
University Medical Center GroningenTrudell Medical InternationalNot yet recruiting
-
Peking Union Medical College HospitalShanghai Reunion Biotech Co.,Ltd.RecruitingUterine Cervical NeoplasmsChina
-
Montefiore Medical CenterRecruiting